PATH
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, PATH sits in the top decile of US sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count).
PATH: 18 sponsored US clinical trials, none currently recruiting.
PATH sponsors 18 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 18 completed. 0 of these trials are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is G6PD Deficiency, with 1 trials.
Top-decile sponsor footprint
PATH ranks in the top decile of sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
18 of 18 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
18 total, page 1 of 1
Controlled Human Infection Model Challenge/Rechallenge
NCT04992520
Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines
NCT04529538
Cholera Anti-Secretory Treatment Trial
NCT04150250
Validation of a Diagnostic Test for Glucose-6-phosphate Dehydrogenase (G6PD) Deficiency in Anti-coagulated Blood
NCT04054661
Validation of Diagnostics to Identify Glucose-6-phosphate Dehydrogenase Activity in the US
NCT04010695
Dose Escalating Study of Intramuscular Invaplex[AR-DETOX]
NCT03869333
Honduras Liger Thermocoagulator Study
NCT03510273
Dose Escalating Study of a Prototype CS6 Subunit Vaccine With a Modified Heat-labile Enterotoxin From Enterotoxigenic Escherichia Coli (ETEC)
NCT03404674
Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine
NCT03300050
Cost-effectiveness Evaluation of Vector Control Strategies in Mozambique
NCT02910934
Dose-Finding Study of Lyophilized Shigella Sonnei 53G Challenge Strain
NCT02816346
Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults
NCT02810340
Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis
NCT02165202
Evaluation of the Performance and Safety of Two Intradermal Delivery Devices.
NCT01943110
A Phase 1 Dose Escalation Study to Examine the Safety of the P2-VP8 Rotavirus Vaccine
NCT01764256
Live Attenuated ETEC Vaccine ACE527 With and Without dmLT Adjuvant in Adults
NCT01739231
Performance and Safety Evaluation of an Intradermal Delivery Device
NCT01359111
Safety Study of Inactivated Shigella Whole Cell Vaccine in Adults
NCT01509846
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 11 |
| Phase 2 | 2 |
Therapeutic Areas
How the PATH early-phase archive is shaped
18 indexed studies, none listed as recruiting (0% open); 18 completed (100%).
Phase mix: 0 late (III/IV) vs 13 early (I/II) (early-phase heavy).
Top condition: G6PD Deficiency (1 trial), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
PATH: archived-pipeline peers nationwide
Peers matched on 18 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
PATH sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 18 archived trials
- ADC Therapeutics S.A. · 18 trials · 11% recruiting
- Akros Pharma · 18 trials · 0% recruiting
- AO Clinical Investigation and Publishing Documentation · 18 trials · 0% recruiting
- AO Innovation Translation Center · 18 trials · 33% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this PATH page
18 registered trials is a research-attention snapshot, not an endorsement of PATH or any single study.
- None of PATH's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- G6PD Deficiency is the condition PATH studies most, compare against other sponsors active in the same condition before evaluating a specific study. See G6PD Deficiency trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
PATH pipeline card: 18 registered trials from official public datasets.Report a data error.